Kyverna Therapeutics filings document a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. Its Form 8-K disclosures frequently cover Regulation FD updates for miv-cel clinical data, business and financial results, and material corporate events involving leadership, board composition, and commercial organization changes.
The company's proxy and governance filings describe director elections, board committees, executive compensation, stockholder voting matters, and equity incentive arrangements, including inducement awards. SEC records also identify Kyverna's Nasdaq-listed common stock and provide formal disclosure around its CAR T development strategy, clinical programs in neuroimmunology, capital planning, risk factors, and public-company governance.
Kyverna Therapeutics (ticker KYTX) filed a Form 4 disclosing that its Chief Financial Officer, Marc Grasso, received an equity award on 30 June 2025. The transaction involves a single grant of 450,000 stock options with an exercise price of $3.07 and an expiration date of 30 June 2035.
The vesting schedule follows a standard four-year pattern: 25 % (112,500 options) vests on 30 June 2026, after which 1⁄48 of the total options (9,375 shares) vest monthly for the next 36 months, contingent on Grasso’s continued employment. The filing shows direct ownership (D) of the derivative security, and no other changes to common-stock holdings were reported.
This award aligns the CFO’s incentives with long-term shareholder value creation and signals a retention commitment by the company. If fully exercised, the award would add up to 450,000 new common shares to the float, a modest potential dilution given Kyverna’s recent post-IPO share count of roughly 55-60 million (based on prior filings). No cash transactions were reported, and the filing contains no earnings or operational updates.